The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
ICICI Direct gives a preview on the earnings narrative for Q3FY22
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Subscribe To Our Newsletter & Stay Updated
